INTRODUCTION
============

Small cell carcinoma of the uterine cervix (SMCC), which comprises about 2% to 5% of most cervical malignancies, tends to be progressive at an early stage, with metastasis to distant organs and lymph nodes, and is known to have a worse prognosis than squamous cell carcinoma or adenocarcinoma of the uterine cervix \[[@B1]-[@B3]\].

Due to the rarity of SMCC, previously reported studies were all conducted in a single institution with a limited number of patients with prognostic factors, such as tumor size and International Federation of Obstetrics and Gynecology (FIGO) stage \[[@B4],[@B5]\], which led to the conclusion that early detection of the disease is important.

The Pap test is a screening test initially introduced to clinical services by George N. Papanicolau in 1939. It has been proved that the test is effective to decreasing the frequency and recurrence rate of the invasive cervical cancer as well as the mortality rate due to the disease. The Pap test is also known to have contributed to prominently cordoning off the development of the invasive cervical cancer through detecting and treating the cervical intraepithelial neoplasia, the very prior stage of the disease \[[@B6]\].

However, in the case of SMCC, the earlier detection rate of SMCC was relatively low due to the rare prevalence of the disease, a growth pattern downward into the epithelium while maintaining a normal epithelium, and the relative tumor location at a high endocervical portion \[[@B7],[@B8]\]. In these regards, it was often reported that, as a screening test, the Pap test for SMCC seemed to be destitute of its diagnostic values and effectiveness itself \[[@B9]-[@B11]\].

The aim of this study is to review the Severance Hospital experience in the patients suffering from the SMCC with a review of the literature.

MATERIALS AND METHODS
=====================

Twenty-seven patients with small cell carcinoma of the uterine cervix were diagnosed and treated at the Severance Hospital from November 1991 to January 2010. The clinical symptoms and chief complaints of the patients at their first clinic visit, age, FIGO clinical stage, and treatment modalities were investigated. The FIGO classification system was used for the determination of disease stages. The survival rate of patients was identified by means of correspondence and telephone.

Physical examination, including Pap smears, of patients was performed every 3 months after treatment. The abdominal and pelvic computed tomography and the magnetic resonance imaging were performed every 6 months, and the patients were carefully followed up. When recurrence was suspected, bone scan and other imaging studies were performed, and biopsy was used to confirm the recurrence, if necessary. If recurrent disease was confirmed, radiation therapy and combination chemotherapy followed. The data were analyzed retrospectively based on the available charts and obtained from pathology reports.

RESULTS
=======

Twenty-seven patients with small cell carcinoma of the uterine cervix were diagnosed between November 1991 and January 2010. Among 27 patients, 18 of them (66.7%) showed symptoms, including vaginal bleeding, at their first clinic visit, and the remaining 9 patients (33.3%) showed abnormal Pap smear screening in the process of their routine health check-up, which were the chief complaints at the first clinic visit. It was reported that the median age of the patients were 54 years (range, 24 to 77 years). Eight of 27 patients were less than 45 years old. FIGO stage IIB was the most common stage (11 of 27 patients) followed by stage IB (9 of 27 patients). In terms of treatment modalities, there were 6 cases (23.1%) who received adjuvant radiation therapy or chemotherapy after radical hysterectomy. In 17 cases (65.4%), combination chemoradiation therapy was performed. Three patients (11.5%) received radical hysterectomy following neoadjuvant chemotherapy ([Table 1](#T1){ref-type="table"}).

The 5-year overall survival rate of 21 patients, who could be followed up, was 57.2%. During the follow-up after primary treatment, 16 cases (59.3%) were reported to be in complete remission status. Six patients showed recurrence after remission. The mean disease-free interval was 9.2 months (range, 6 to 11 months) in the recurrent cases. Recurrence sites included the para-aortic lymph nodes (n=3), bone (n=3), lung (n=2), neck nodes (n=2), liver (n=1), and brain (n=1) ([Table 2](#T2){ref-type="table"}).

Of 9 patients who showed abnormal Pap smear screening results, 2 were diagnosed as squamous cell carcinoma, and 2 cases as small cell carcinoma on the initial cytologic diagnosis. In addition, 2 cases were diagnosed as atypical squamous cells of undetermined significance (ASCUS), and 3 cases as high-grade squamous intraepithelial lesions (HSIL), respectively. At the final histologic diagnosis, only one case was identified as the mixture of small cell carcinoma and a squamous cell component, and 8 cases as small cell carcinoma of the uterine cervix. The diagnostic accuracy of the cytologic findings was 22.2% ([Table 3](#T3){ref-type="table"}). For 9 patients with abnormal Pap smear screening results, there were 5 cases (55.6%) of stage IB, 3 cases (33.3%) of stage IIB, and 1 case (11.1%) of stage III.

DISCUSSION
==========

The rare prevalence of SMCC makes its diagnosis difficult and at the same time decreases the sensitivity of cytologic diagnosis. According to Kim et al. \[[@B9]\], the diagnostic accuracy of cytologic smears in diagnosing SMCC is low (approximately 38.5%). In addition, Wang et al. \[[@B10]\] reported that only 46% of the patients diagnosed with SMCC were diagnosed as having abnormal or malignant growths in cytologic smears, and Zhou et al. \[[@B11]\] reported that only 14% were diagnosed with abnormal or malignant growths. There was no patient diagnosed with SMCC in the cytology smears in both studies. In this study, only two of the nine patients with abnormal Pap smear results were diagnosed with SMCC, resulting in 22.2% in terms of diagnostic accuracy with the cytologic findings.

It is known that SMCC shows a histological finding and prognosis that are similar to those of small cell carcinoma of the lung. SMCC shows rapid progression and early metastasis commonly occurring in the lymph nodes or other organs, leading to a 60-82% lymph lumen invasion and a 40-60% pelvic lymph node metastasis at the time of diagnosis \[[@B12],[@B13]\]. Sheets et al. \[[@B14]\] reported that when surgical treatment was conducted on patients with early-stage SMCC, nodal metastasis was found in approximately 57% of the patients. In addition, Sevin et al. \[[@B3]\] reported that, unlike squamous-cell carcinoma or adenocarcinoma of the uterine cervix, SMCC shows a shallow depth of invasion and a small tumor size, yet is an aggressive neoplasm that has a higher incidence of lymphovascular space involvement and lymph node metastasis.

The outcome of SMCC is associated with the disease stage. Chan et al. \[[@B15]\] reported that, in the case of an early-stage disease, where the disease is limited within the radiation field, combined-modality therapy showed approximately 30% treatment success. On the other hand, in the case of an advanced-stage disease, the prognosis was too bad to find survivors over two years. Due to the rare prevalence of this disease, the number of study specimens seen at a single institution was relatively small, and prognostic factors, such as the tumor size, LN involvement, and FIGO stage, were identified \[[@B4],[@B5]\]. In this study, FIGO stage IIB was the most common stage (11 of 27 patients), and the 5-year overall survival rate of 21 patients who could be followed up was reported to be 57.2%.

As the pathophysiology of SMCC is similar to that of small cell carcinoma of the lung (SCLC), SMCC treatment can also be deduced from the treatment of SCLC. It has been continually reported that, if an anticancer agent that is used for the treatment of general uterine cervical cancer is used, the survival rate of SMCC patients will be 33%; however, if an anticancer agent that is used for the treatment of SCLC is used, the survival rate will be 68%, showing a statistically significant difference. This suggests that the anticancer agent used for the treatment of SCLC can be used for the postoperative adjuvant chemotherapy regimen of SMCC \[[@B12]\]. In fact, other researchers reported that chemotherapy in combination with cisplatin and etoposide, and radiotherapy used for the treatment of SCLC, were applied to SMCC patients and successfully treated approximately 55% of the patients \[[@B16]\].

According to a large-scale multicenter retrospective study that was conducted involving 68 stage IB-IIA patients who underwent surgery, neoadjuvant chemotherapy results in the downsizing of a bulky mass into an appropriate size for surgery, but had no benefit in the overall survival rate. In addition, adjuvant chemoradiation therapy after surgery contributed less to the survival rate than adjuvant chemotherapy alone. Therefore, it was concluded that, for early-stage SMCC, primary radical surgery followed by adjuvant chemotherapy should be conducted as a preferable treatment modality \[[@B17]\].

Although this study suffered from limited case samples, it was consistent with the concept that Pap smear screening might not be helpful in early diagnosis of SMCC considering its low diagnostic accuracy. In the light of its low prevalence, a large-scale multicenter prospective study may be required to improve its diagnosis and treatment.
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Values are presented as number (%) unless otherwise indicated.

RH: radical hysterectomy, RTx: radiation therapy, CTx: chemotherapy, Tx: therapy.
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The 5 year overall survival rate and recurrence of the patients
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Values are presented as number (%) unless otherwise indicated.

FIGO: International Federation of Obstetrics and Gynecology, LN: lymph node.
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Clinical features and cytologic findings of the abnormal Pap smear results
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Dx: diagnosis, FIGO: International Federation of Obstetrics and Gynecology, SCC: squamous cell carcinoma, SMCC: small cell carcinoma of the uterine cervix, RH: radical hysterectomy, RTx: radiation therapy, NED: live with no evidence of disease, LN: lymph node, Tx: therapy, ASCUS: atypical squamous cells of undetermined significance, HSIL: high-grade squamous intraepithelial lesion, UK: dead of unknown causes, CTx: chemotherapy, DoD: dead of disease.
